
    
      A Multi-Center Phase I Study of NeuroVaxâ„¢, a Novel Therapeutic TCR Peptide Vaccine for
      Pediatric Multiple Sclerosis to demonstrate safety & efficacy 12 subjects with pediatric MS
    
  